NCT01688635View on ClinicalTrials.gov

A Study to Compare LY2963016 and US-approved Lantus® After Single Dose Administration to Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Healthy
Interventions
DRUG

LY2963016

Administered subcutaneously

DRUG

US Approved Lantus

Administered subcutaneously

Trial Locations (1)

117597

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Singapore

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT01688635 - A Study to Compare LY2963016 and US-approved Lantus® After Single Dose Administration to Healthy Participants | Biotech Hunter | Biotech Hunter